骨巨细胞瘤治疗用药狄诺塞麦注意事项

Have you read the package insert for (Denosumab)? The side effects and precautions in the drug instructions are what our patients should understand most. Now the editor will mainly give you a brief introduction to the precautions for denosumab (desosumab).

Denosumab (desosumab) is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. The mRNA of human RANKL is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts.

Compared with bisphosphonates that have been clinically used for a long time, denosumab (desosumab) has the advantage of significantly prolonging the occurrence time of bone damage-related events; it can be administered subcutaneously and is easy to use, and clinical data shows that the drug does not require monitoring of renal function, while the use of bisphosphonates must be based on the patient's renal function monitoring to determine the dosing rate. degree; however, denosumab (desosomeb) is currently relatively expensive, and the balance between its long-term efficacy and cost-effectiveness needs to be further confirmed. It is expected that denosumab (desosomeb), a drug that specifically targets RANK ligand inhibitors, can obtain more valuable research results in the treatment of solid tumors and bring new hope to patients with bone metastasis.

What are the precautions for denosumab (desosumab)?

Hypocalcemia must be corrected before initiating treatment with denosumab. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

Patients who are also taking immunosuppressants or have compromised immune systems may be at increased risk of serious infections. Physicians must fully consider the benefit and risk ratio before prescribing denosumab to such patients. Physicians should evaluate the need to continue denosumab treatment in patients who develop serious infections while taking denosumab. Osteonecrosis of the jaw often occurs with tooth extraction and local infection that delays healing. A routine oral examination should be performed before starting treatment with (Denosumab), and good oral hygiene should be maintained after treatment is started. If a patient develops osteonecrosis of the jaw, treatment for osteonecrosis of the jaw may worsen the condition, and discontinuation of the medication should be considered at this time.

Recommended related hot articles: /newsDetail/78005.html